Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.

BACKGROUND Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes. We conducted a multicenter randomized trial to compare quality-of-life outcomes between patients with clinically node-negative invasive breast cancer who received sentinel lymph node biopsy and patients who received standard axillary treatment. METHODS The primary outcome measures were arm and shoulder morbidity and quality of life. From November 1999 to October 2003, 1031 patients were randomly assigned to undergo sentinel lymph node biopsy (n = 515) or standard axillary surgery (n = 516). Patients with sentinel lymph node metastases proceeded to delayed axillary clearance or received axillary radiotherapy (depending on the protocol at the treating institution). Intention-to-treat analyses of data at 1, 3, 6, and 12 months after surgery are presented. All statistical tests were two-sided. RESULTS The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively. Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P < .001), and axillary operative time was reduced (P = .055). Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P < or = .003). These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P > .05). CONCLUSION Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.

[1]  Mary J. Nissen,et al.  Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer , 2002, Annals of Surgical Oncology.

[2]  H. Thaler,et al.  Sensory morbidity after sentinel lymph node biopsy and axillary dissection: A prospective study of 233 women , 2002, Annals of Surgical Oncology.

[3]  E. Venkatraman,et al.  Impact of sentinel lymph node mapping on relative charges in patients with early-stage breast cancer , 2000, Annals of Surgical Oncology.

[4]  R. Newcombe,et al.  Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer – results of the ALMANAC validation phase , 2006, Breast Cancer Research and Treatment.

[5]  R. Newcombe,et al.  The learning curve in sentinel node biopsy: The ALMANAC experience , 2004, Annals of Surgical Oncology.

[6]  R. Newcombe,et al.  Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer , 2006, Breast Cancer Research and Treatment.

[7]  E. Winer,et al.  American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Duffy,et al.  Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Newcombe,et al.  Clinical relevance of internal mammary node drainage in sentinel node biopsy for breast cancer , 2005 .

[10]  A. Luini,et al.  Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. , 2005, European journal of cancer.

[11]  ASCO Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: Guideline Summary. , 2005, Journal of oncology practice.

[12]  J. Cuzick,et al.  Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Cody,et al.  The Risk of Axillary Relapse After Sentinel Lymph Node Biopsy for Breast Cancer Is Comparable With That of Axillary Lymph Node Dissection: A Follow-up Study of 4008 Procedures , 2004, Annals of surgery.

[14]  D. Neuberg,et al.  A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. , 2004, Journal of clinical epidemiology.

[15]  R. Mansel,et al.  European studies on breast lymphatic mapping. , 2004, Seminars in oncology.

[16]  U. Chetty,et al.  Sentinel lymph node biopsy in male breast cancer patients. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  A. Haid,et al.  Morbidity of Breast Cancer Patients Following Complete Axillary Dissection or Sentinel Node Biopsy Only: A Comparative Evaluation , 2002, Breast Cancer Research and Treatment.

[18]  L. Fallowfield,et al.  The validation of a quality of life scale to assess the impact of arm morbidity in breast cancer patients post-operatively , 2001, Breast Cancer Research and Treatment.

[19]  F. Peintinger,et al.  Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients , 2003, British Journal of Cancer.

[20]  Umberto Veronesi,et al.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. , 2003, The New England journal of medicine.

[21]  D. Cella,et al.  What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. , 2002, Journal of clinical epidemiology.

[22]  S. Hollenbeck,et al.  Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. , 2002, American journal of surgery.

[23]  K. McMasters,et al.  Defining the Optimal Surgeon Experience for Breast Cancer Sentinel Lymph Node Biopsy: A Model for Implementation of New Surgical Techniques , 2001, Annals of surgery.

[24]  K. Kahn,et al.  Arm edema in breast cancer patients. , 2001, Journal of the National Cancer Institute.

[25]  A E Giuliano,et al.  Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Andreas Shamiyeh,et al.  Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma , 2000, Cancer.

[27]  D. Roses,et al.  Complications of level I and II axillary dissection in the treatment of carcinoma of the breast. , 1999, Annals of surgery.

[28]  V. Velanovich,et al.  Quality of life of breast cancer patients with lymphedema. , 1999, American journal of surgery.

[29]  L Cohen,et al.  Physical and psychological morbidity after axillary lymph node dissection for breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Winer,et al.  Complications of axillary lymph node dissection for carcinoma of the breast , 1998, Cancer.

[31]  R. Newcombe,et al.  Interval estimation for the difference between independent proportions: comparison of eleven methods. , 1998, Statistics in medicine.

[32]  A. Giuliano,et al.  Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. , 1997, Annals of surgery.

[33]  D S Tulsky,et al.  Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Brisson,et al.  Arm problems and psychological distress after surgery for breast cancer. , 1993, Canadian journal of surgery. Journal canadien de chirurgie.

[35]  B. Achinstein,et al.  Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. , 2009, Nutrition reviews.

[36]  R. Steele,et al.  The efficacy of lower axillary sampling in obtaining lymph node status in breast cancer: A controlled randomized trial , 1985, The British journal of surgery.

[37]  M Nurminen,et al.  Comparative analysis of two rates. , 1985, Statistics in medicine.

[38]  C. Spielberger,et al.  Manual for the State-Trait Anxiety Inventory , 1970 .

[39]  E. B. Wilson.  Probable Inference, the Law of Succession, and Statistical Inference , 1927 .